Cargando…

The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

BACKGROUND: Fractional exhaled nitric oxide (FENO) has been shown to be a marker of airway inflammation in various pulmonary diseases, including chronic obstructive pulmonary disease (COPD). In this study, we assessed the FENO level in patients with acute exacerbations of COPD (AECOPD) and analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Aiyuan, Zhou, Zijing, Deng, Dingding, Zhao, Yiyang, Duan, Jiaxi, Cheng, Wei, Liu, Cong, Chen, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522317/
https://www.ncbi.nlm.nih.gov/pubmed/33061343
http://dx.doi.org/10.2147/COPD.S263673
_version_ 1783588153732366336
author Zhou, Aiyuan
Zhou, Zijing
Deng, Dingding
Zhao, Yiyang
Duan, Jiaxi
Cheng, Wei
Liu, Cong
Chen, Ping
author_facet Zhou, Aiyuan
Zhou, Zijing
Deng, Dingding
Zhao, Yiyang
Duan, Jiaxi
Cheng, Wei
Liu, Cong
Chen, Ping
author_sort Zhou, Aiyuan
collection PubMed
description BACKGROUND: Fractional exhaled nitric oxide (FENO) has been shown to be a marker of airway inflammation in various pulmonary diseases, including chronic obstructive pulmonary disease (COPD). In this study, we assessed the FENO level in patients with acute exacerbations of COPD (AECOPD) and analyzed the predictive value of the FENO level for treatment response. METHODS: Demographic data were collected at admission. FENO, lung function, blood gases, COPD Assessment Test (CAT), and modified Medical Research Council (mMRC) scores were measured at admission and on day 7. At the second visit, the patients were asked to report their health status; scores ranged from 1 to 5, representing “much better”, “slightly better”, “no change”, “slightly worse”, and “much worse”, respectively. The treatment response was evaluated based on the patient’s reported health status (responders were those who reported much better and slightly better) and lung function (responders were those who presented an increase in FEV(1) over 200 mL). RESULTS: A total of 182 patients were recruited into the analysis. The FENO level positively correlated with an increase in FEV(1) and FEV(1)% (r = 0.291, p < 0.001 and r = 0.205, p = 0.005, respectively), but negatively correlated with a decrease in the COPD Assessment Test (CAT) score (r = −0.197, p = 0.008) and patient-reported health status (rho = −0.408, p<0.001). An inverse correlation was observed between FENO concentrations at admission and the length of hospital stay. The cut-off point for differentiating responders, identified by health status, was 18 ppb, with the sensitivity being 89.7% and specificity 88.9%. CONCLUSION: FENO levels, determined at hospital admission, are potential to predict the overall treatment response in AECOPD patients, including remission in subjective patient-reported health statuses and, also, improvements in lung function. REGISTRY NUMBER: ChiCTR-ROC-16,009,087 (http://www.chictr.org.cn/).
format Online
Article
Text
id pubmed-7522317
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75223172020-10-14 The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Zhou, Aiyuan Zhou, Zijing Deng, Dingding Zhao, Yiyang Duan, Jiaxi Cheng, Wei Liu, Cong Chen, Ping Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Fractional exhaled nitric oxide (FENO) has been shown to be a marker of airway inflammation in various pulmonary diseases, including chronic obstructive pulmonary disease (COPD). In this study, we assessed the FENO level in patients with acute exacerbations of COPD (AECOPD) and analyzed the predictive value of the FENO level for treatment response. METHODS: Demographic data were collected at admission. FENO, lung function, blood gases, COPD Assessment Test (CAT), and modified Medical Research Council (mMRC) scores were measured at admission and on day 7. At the second visit, the patients were asked to report their health status; scores ranged from 1 to 5, representing “much better”, “slightly better”, “no change”, “slightly worse”, and “much worse”, respectively. The treatment response was evaluated based on the patient’s reported health status (responders were those who reported much better and slightly better) and lung function (responders were those who presented an increase in FEV(1) over 200 mL). RESULTS: A total of 182 patients were recruited into the analysis. The FENO level positively correlated with an increase in FEV(1) and FEV(1)% (r = 0.291, p < 0.001 and r = 0.205, p = 0.005, respectively), but negatively correlated with a decrease in the COPD Assessment Test (CAT) score (r = −0.197, p = 0.008) and patient-reported health status (rho = −0.408, p<0.001). An inverse correlation was observed between FENO concentrations at admission and the length of hospital stay. The cut-off point for differentiating responders, identified by health status, was 18 ppb, with the sensitivity being 89.7% and specificity 88.9%. CONCLUSION: FENO levels, determined at hospital admission, are potential to predict the overall treatment response in AECOPD patients, including remission in subjective patient-reported health statuses and, also, improvements in lung function. REGISTRY NUMBER: ChiCTR-ROC-16,009,087 (http://www.chictr.org.cn/). Dove 2020-09-24 /pmc/articles/PMC7522317/ /pubmed/33061343 http://dx.doi.org/10.2147/COPD.S263673 Text en © 2020 Zhou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Aiyuan
Zhou, Zijing
Deng, Dingding
Zhao, Yiyang
Duan, Jiaxi
Cheng, Wei
Liu, Cong
Chen, Ping
The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
title The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
title_full The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
title_fullStr The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
title_full_unstemmed The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
title_short The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
title_sort value of feno measurement for predicting treatment response in patients with acute exacerbation of chronic obstructive pulmonary disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522317/
https://www.ncbi.nlm.nih.gov/pubmed/33061343
http://dx.doi.org/10.2147/COPD.S263673
work_keys_str_mv AT zhouaiyuan thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT zhouzijing thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT dengdingding thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT zhaoyiyang thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT duanjiaxi thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT chengwei thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT liucong thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT chenping thevalueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT zhouaiyuan valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT zhouzijing valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT dengdingding valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT zhaoyiyang valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT duanjiaxi valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT chengwei valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT liucong valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease
AT chenping valueoffenomeasurementforpredictingtreatmentresponseinpatientswithacuteexacerbationofchronicobstructivepulmonarydisease